<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004266</url>
  </required_header>
  <id_info>
    <org_study_id>199/11643</org_study_id>
    <secondary_id>UMN-1967</secondary_id>
    <secondary_id>R01DK047112</secondary_id>
    <nct_id>NCT00004266</nct_id>
  </id_info>
  <brief_title>Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes</brief_title>
  <official_title>Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hennepin County Medical Center, Minneapolis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Establish a long-term working relationship between clinical investigators and the&#xD;
      Minnesota American Indian community.&#xD;
&#xD;
      II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and&#xD;
      nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in&#xD;
      Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria.&#xD;
&#xD;
      III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A&#xD;
      reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol&#xD;
      Education Program in preventing nephropathy and vascular diseases in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      Patients are randomly assigned to 1 of 4 treatment groups; therapy continues for 3 years. All&#xD;
      patients receive instruction on diet, exercise, and smoking cessation.&#xD;
&#xD;
      The first group receives daily nifedipine at a dose adjusted for high blood pressure.&#xD;
      Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program&#xD;
      guidelines. Diuretics and doxazosin may be given concurrently.&#xD;
&#xD;
      The second group receives daily lisinopril at a dose adjusted for high blood pressure.&#xD;
      Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program&#xD;
      guidelines. Diuretics and doxazosin may be given concurrently.&#xD;
&#xD;
      The third group receives daily nifedipine at a dose adjusted for high blood pressure, and&#xD;
      simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine&#xD;
      may be given as needed. If cholestyramine is not tolerated or if triglycerides are high,&#xD;
      gemfibrozil is substituted for cholestyramine.&#xD;
&#xD;
      The fourth group receives lisinopril at a dose adjusted for high blood pressure and&#xD;
      simvastatin at a dose adjusted for high low-density lipoproteins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1993</start_date>
  <completion_date type="Actual">July 1999</completion_date>
  <primary_completion_date type="Actual">July 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine and simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril and simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_label>Lisinopril and simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_label>Nifedipine and simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <arm_group_label>Lisinopril and simvastatin</arm_group_label>
    <arm_group_label>Nifedipine and simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Non-insulin-dependent diabetes mellitus with documented fasting&#xD;
        hyperglycemia Microalbuminuria OR clinically detectable albuminuria; Urine albumin&#xD;
        excretion rate at least 30 mg/24 hours Low-density lipoproteins (fasting) at least 80 mg/dL&#xD;
        Recruitment from American Indian population at Red Lake and Leech Lake reservations&#xD;
&#xD;
        --Prior/Concurrent Therapy-- At least 5 days since antihypertensives or antilipemics&#xD;
&#xD;
        --Patient Characteristics-- Renal: Urine albumin-to-creatinine ratio at least 30 mg/g;&#xD;
        Creatinine clearance or estimated creatinine clearance at least 30 mL/min; No active urine&#xD;
        sediment suggestive of glomerulonephritis, i.e.: No RBCs greater than 10/high-power field;&#xD;
        No WBCs greater than 15/high-power field; No RBC casts&#xD;
&#xD;
        Cardiovascular: No symptomatic orthostatic hypotension; No poorly-compensated congestive&#xD;
        heart failure; No requirement for angiotensin-converting enzyme inhibitors; No angina&#xD;
        pectoris requiring nifedipine; No unstable angina; No episodes of angina occurring more&#xD;
        than once a month; No chest pain of undetermined cause within 1 month; No severe&#xD;
        hypertension requiring multiple antihypertensives; No myocardial infarction within 1 year;&#xD;
        No stroke or transient ischemic attack within 1 year&#xD;
&#xD;
        Other: No known allergy to nifedipine, lisinopril, or simvastatin; No untreated&#xD;
        proliferative retinopathy; Documented retinal exam within 1 year prior to entry; No alcohol&#xD;
        or drug abuse affecting compliance; No other debilitating or acute illness; No pregnant or&#xD;
        nursing women; Effective contraception required of fertile women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram L. Kasiske</last_name>
    <role>Study Chair</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic nephropathy</keyword>
  <keyword>rare disease</keyword>
  <keyword>renal and genitourinary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

